U.S. markets open in 2 hours 35 minutes

Seer, Inc. (SEER)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
40.09-1.71 (-4.09%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close41.80
Open42.54
Bid38.87 x 800
Ask41.23 x 900
Day's Range40.00 - 42.54
52 Week Range38.37 - 86.55
Volume356,218
Avg. Volume524,491
Market Cap2.459B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est63.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Seer to Present at the BofA Securities 2021 Healthcare Conference
      GlobeNewswire

      Seer to Present at the BofA Securities 2021 Healthcare Conference

      REDWOOD CITY, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will be participating virtually in the upcoming BofA Securities 2021 Healthcare Conference. Seer’s management is scheduled to participate in a fireside chat on Thursday, May 13 at 10:15 a.m. Pacific Time / 1:15 p.m. Eastern Time. A live webcast of the virtual session will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the conference. About SeerSeer is a life sciences company developing transformative products that open up a new gateway to the proteome. Seer is commercializing its Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy-to-use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be adopted by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio. Investor ContactCarrie Mendivilinvestor@seer.bio Media ContactKaren Possematopr@seer.bio

    • Seer to Report First Quarter Financial Results on May 10, 2021
      GlobeNewswire

      Seer to Report First Quarter Financial Results on May 10, 2021

      REDWOOD CITY, Calif., April 12, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report financial results for the first quarter 2021 after market close on Monday, May 10, 2021. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the event. About SeerSeer is a life sciences company focused on enabling exceptional scientific outcomes by commercializing transformative products that will drive breakthrough ideas by unlocking the deep, unbiased biological information that can make them a reality. Seer is developing its Proteograph™ Product Suite, which is an integrated solution consisting of consumables, automation instrumentation and proprietary software that performs deep, unbiased proteomics analysis at scale in a matter of hours. Seer designed the Proteograph Product Suite to be efficient and easy-to-use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that is broadly available to life sciences researchers. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio. Investor ContactCarrie Mendivilinvestor@seer.bio Media ContactKaren Possematopr@seer.bio

    • Seer, Inc. (SEER) Q4 2020 Earnings Call Transcript
      Motley Fool

      Seer, Inc. (SEER) Q4 2020 Earnings Call Transcript

      Earlier today, Seer released financial results for the fourth quarter and full year ending December 31, 2020. Joining me today from Seer is Omid Farokhzad, chairman, chief executive officer, and founder; Omead Ostadan, president and chief operating officer; and David Horn, chief financial officer.